Matrix Metalloproteinase-2 and -9 Secreted by Leukemic Cells Increase the Permeability of Blood-Brain Barrier by Disrupting Tight Junction Proteins by Feng, Saran et al.
Matrix Metalloproteinase-2 and -9 Secreted by Leukemic
Cells Increase the Permeability of Blood-Brain Barrier by
Disrupting Tight Junction Proteins
Saran Feng
1,3, Jiannong Cen
1, Yihong Huang
2, Hongjie Shen
1, Li Yao
1, Yuanyuan Wang
1, Zixing Chen
1*
1Leukemia Research Unit, Jiangsu Institute of Hematology, 1st Affiliated Hospital, Soochow University, Key Laboratory of Thrombosis and Hemostasis Ministry of Health,
Suzhou, China, 2Department of Hematology, Affiliated Hospital, Xuzhou Medical College, Xuzhou, China, 3Department of Hematology, Xuzhou Central Hospital, Xuzhou,
China
Abstract
Central nervous system (CNS) involvement remains an important cause of morbidity and mortality in acute leukemia, the
mechanisms of leukemic cell infiltration into the CNS have not yet been elucidated. The blood-brain barrier (BBB) makes
CNS become a refugee to leukemic cells and serves as a resource of cells that seed extraneural sites. How can the leukemic
cells disrupt this barrier and invasive the CNS, even if many of the currently available chemotherapies can not cross the BBB?
Tight junction in endothelial cells occupies a central role in the function of the BBB. Except the well known role of degrading
extracellular matrix in metastasis of cancer cells, here we show matrix metalloproteinase (MMP)-2 and -9, secreted by
leukemic cells, mediate the BBB opening by disrupting tight junction proteins in the CNS leukemia. We demonstrated that
leukemic cells impaired tight junction proteins ZO-1, claudin-5 and occludin resulting in increased permeability of the BBB.
However, these alterations reduced when MMP-2 and -9 activities were inhibited by RNA interference strategy or by MMP
inhibitor GM6001 in an in vitro BBB model. We also found that the disruption of the BBB in company with the down-
regulation of ZO-1, claudin-5 and occludin and the up-regulation of MMP-2 and -9 in mouse brain tissues with leukemic cell
infiltration by confocal imaging and the assay of in situ gelatin zymography. Besides, GM6001 protected all mice against CNS
leukemia. Our findings suggest that the degradation of tight junction proteins ZO-1, claudin-5 and occludin by MMP-2 and
-9 secreted by leukemic cells constitutes an important mechanism in the BBB breakdown which contributes to the invasion
of leukemic cells to the CNS in acute leukemia.
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Introduction
The central nervous system (CNS) is one of the most frequent
extramedullary locations in acute leukemia (AL). The prognosis of
patients with isolated or mixed CNS relapse is particularly poor.
Despite of all kinds of morden therapies (systemic chemotherapy
and cranial irradiation) it has become a major obstacle to curing
acute leukemia [1–5]. Despite its clinical importance, how
leukemic cells enter the CNS is poorly understood. The
characteristic structure of the blood-brain barrier (BBB) causes
the CNS to serve as a resource of cells that seed extraneural sites.
But much needs to be learned about how can the leukemic cells
disrupt this barrier and invasive the CNS, even if many of the
currently available chemotherapies cannot cross the BBB.
Moreover, little is known about cellular response of cerebral
endothelial cells during invasion of leukemic cell to the CNS.
It is known that the BBB breakdown is associated with brain
tumors and diseases of the central nervous system. Although the
disruption of the extracellular matrix (ECM) can lead to increased
permeability of the BBB in pathological states [6], it is primarily
the tight junction (TJ) between adjacent brain microvascular
endothelial cells (BMVECs) that confers low paracellular perme-
ability and high electrical resistance, making the barrier to
function 50,100 times tighter than peripheral microvessels [7–
9]. TJs are composed of transmembrane molecules (claudin,
occludin and junctional adhesion molecules) linked to the actin
cytoskeleton through cytoplasmic accessory proteins, including
zonula occludens (ZO)-1, ZO-2 and ZO-3 [10,11]. Claudin-5 and
occludin were identified as key components of BBB integrity which
are localized at the leading edge of BMVECs. ZO-1 acts as a
crucial central regulator of the structural organization of the TJ at
the plasma membrane [11]. While the barrier and fence functions
of TJ have been well understood, it is only relatively recently that
the association between TJ and metastasis of cancer cells has been
recognized. It is becoming increasingly clear that the TJs have a
vital role in maintaining cell to cell integrity and that the loss of
cohesion of the structure can lead to invasion and thus metastasis
of cancer cells [12,13].
Some members of the matrix metalloproteinase (MMP) family
like MMP-2 and -9 are known to be associated with tumor growth
and metastasis because of their capacity to degrade collagen IV,
the major ECM component [14]. Earlier reports show an
association of MMP-2/-9 expression with invasive behaviour of
leukemic cells in acute lymphoblastic leukemia (ALL) and acute
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appears to have prognostic impact in AML [16]. Considerable
evidence has accumulated that in some CNS diseases MMP-2 and
-9 are involved in the permeability of the BBB by disrupting the
junction complexes such as occludin and claudin-5 [18–21]. We
have thus hypothesized that MMP-2 and -9 secreted by leukemic
cells may play critical roles in the BBB opening in CNS leukemia
by disrupting TJ proteins.
In order to investigate this hypothesis, we examined the
relationship of MMP-2 and -9 secreted by leukemic cells with
the TJ proteins and the BBB dysfunction in an in vitro model of
BBB and in an animal model of CNS leukemia. We show that
leukemic cell-derived MMP-2 and -9 disrupt the key TJ proteins
ZO-1, claudin-5 and occludin and that this is correlated with the
BBB opening. Down-regulation of MMP-2 and -9 secreted by
leukemic cells reduces the disruption of these three proteins with
decreased permeability of the BBB and also protect mice against
CNS leukemia. These data implicate MMP-2 and -9-mediated
down-regulation of TJ proteins as a significant mechanism in the
breakdown of the BBB, which contributes to the metastatic
dissemination of leukemic cells in CNS leukemia.
Materials and Methods
Ethics statement
All animal work was done following an institutionally approved
protocol in accordance with National Health Guides for the Care
and Use of Laboratory Animals and the Law of Animal
Experiments regulation of the University of Soochow (26/2008).
All surgery was performed under chloral hydrate anesthesia, and
all efforts were made to minimize suffering.
Mice
Four-week-old male BALB/c nu/nu mice were purchased from
the Shanghai Laboratory Animals Center of the Chinese Academy
of Science and maintained under specific pathogen-free condi-
tions. All mice were pretreated as follows: splenectomized on day
0, 2.5 mg cytoxan intraperitoneal injection for three days, surgery
after seven days and total body sublethal irradiation of 4.0 Gy at
rate of 2 Gy/min per dose on day 10. Those mice that received
splenectomy, cytoxan intraperitoneal injection, and were pretreat-
ed with sublethal irradiation (SCI), were referred to as SCI-nu/nu
mice.
Cell culture, reagents and treatments
Leukemic cell line SHI-1 was originally derived from the bone
marrow mononuclear cells of a patient with acutemonocytic
leukemia in relapse, and maintained as an in vitro cell line [22].
SHI-1, NB4 and U937 cells were available and carried in our
laboratory. Cells were maintained in Iscove’s Modified Dulbecco’s
Medium (IMDM) (Gibco, USA) with a 10% fetal bovine serum
(FBS) (Gibco, USA) at 37uC in a humidified atmosphere
containing 5% CO2.
Primary human BMVECs were purchased from the American
Sciencell Research Laboratory and cultured in a complete serum
of endothelial cell medium (Sciencell, USA) in tissue culture flasks
pre-coated with human fibronectin (3 mg/cm, Gibco, USA).
Endothelial cells achieved 70,80% confluence after 5 to 7 days.
Following two passages digested with trypsin/EDTA solution, the
cells were used to set experiments.
The broad-spectrum MMP inhibitor GM6001 (Calbiochem,
Germany) was dissolved in dimethyl sulfoxide (DMSO) as a stock
solution and further supplemented in PBS immediately before
administration or in IMDM before incubation with leukemic cells.
For inhibition studies, cells were incubated with 20 mg/ml (the
concentration that highly inhibited the activities of MMP-2 and -9
in leukemic cells but had no influence on cell viability) GM6001.
Cell viability was analyzed by trypan staining, which indicated cell
survival rates of .95%.
Transfection of SHI-1 cells with siRNA
MMP-2 and -9 genes of SHI-1 cells were knocked down by
RNAi. A specific siRNA of MMP-2 was designed given the
protocol suggested by Ries et al [23]. A specific siRNA of MMP-9
was designed by Genepharma (China). The sequences were as
follows: sense, 59-GAC CUG AGA ACC AAU CUC ATT-39;
antisense, 59-UGA GAU UGG UUC UCA GGU CTT-39. All
oligonucleotides were synthesized by Genepharma. SiRNA
transfection of SHI-1 was performed as previously described by
us [24].
Zymography
The activities of MMP-2 and -9 in the conditioned medium
were determined by gelatin zymography as previously described
[25]. Supernatants of different leukemia cell lines treated or
untreated with GM6001, as well as the RNAi-treated cells for 24 h
after transfection at the final density of 2.0610
5 cells/well
suspended in serum-free medium (IMDM 100 ml) were seeded in
96-well plates. Supernatants were harvested after 24 h cultivation
and 15 ml serum-free medium were collected and clarified by
centrifugation to remove cells and debris. Samples were loaded
under nonreducing conditions onto SDS-polyacrylamide gel
polymerized with 1 mg/ml gelatin. Following electrophoresis,
the gels were washed with 2.5% Triton X-100 to remove SDS and
then incubated in a developing buffer [50 mM Tris–Cl pH 7.5,
10 mM CaCl2, 150 mM NaCl, 1 mM ZnCl2, 0.02%NaN3]
overnight at 37uC. Gels were stained with 0.25% Coomassie
Brilliant Blue R-250 and destained in the same solution without
dye. Gelatinase activity was visualized as clear bands against the
blue-stained gelatin background and analyzed in a computer
system. Three individual experiments were conducted with
independent protein samples.
In vitro BBB model and evaluation of the barrier integrity
An in vitro BBB model composed of BMVECs was developed on
a matrigel-based insert with 8.0 mm pore size in a 24-well plate.
Growth-arrested BMVECs of 2610
4 were seeded onto the upper
surface of matrigel and fibronectin-coated polycarbonate mem-
branes in transwell culture chambers. After the cells were
incubated for 5–8 d to allow cell attachment, we carried out our
experiments. The permeability of the barrier and the formation of
the monolayer and its tightness were judged by measuring
dextran-FITC (100 mg/ml, 40 Kd, Molecular Probes) flux across
the barrier by flow cytometry analysis. The matrigel-based insert
without BMVECs was used as control. When the dextran-FITC
became absent in the lower compartment, the model was used to
set experiments.
Invasion and cell migration assay
Twenty-four-well transwell inserts with 8 mm pores coated with
matrigel (50 mL/well; BD Biosciences, Palo Alto, CA) were used to
assesscellinvasion. Different leukemia cell lines treatedor untreated
with GM6001, as well as the RNAi-treated cells for 24 h were
suspended in 200 ml serum-free IMDM medium and seeded at a
final density of 2.0610
5 cells/well in triplicate in the upper
chamber. The lower compartment of the invasion chamber was
filled with 800 ml IMDM (supplemented with 10% human serum)
Mechanism of Central Nervous System Leukemia
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coated filter inserts with or without seeded BMVECs (2.0610
4 cells)
were placed into the wells forming the upper compartment. The
chambers were incubated for 24 h at 37uC in a 5% CO2
atmosphere. Cells that had migrated into the lower compartment
werecounted andtheinvasionratewascalculatedbythe ratio ofthe
number of cells in the medium of lower compartment to the total
number of leukemic cells loaded in the upper compartment.
Morphologic changes of BMVECs on matrigel were observed
under inverted phase contrast microscopy after washed with PBS.
Photographs were captured using a camera (Canon A1000,
Malaysia). Each invasion experiment was performed in triplicate.
Murine CNS leukemia model and drug administration
For CNS leukemia animal model, a total of 1.2610
7 SHI-1 cells
in 0.01 M PBS for a total volume of 200 ml were inoculated into 46
SCI-nu/nu mice via the dorsal tail vein after receiving sublethal
irradiation. 46 SCI-nu/nu mice were randomized into 4 groups: 30
SCI-nu/nu mice were only inoculated with SHI-1 cells, 8 SCI-nu/
nu mice were injected intraperitoneally with GM6001 (1.5 mg per
mouse) daily until day 21, another 6 SCI-nu/nu mice were injected
with PBS without SHI-1 cells and 2 mice were injected with the
vehicle DMSO as control. Mice were monitored daily for survival
and clinical appearance of nerve palsy and killed when becoming
moribund. In order to identify the initial time of leukemic cells
entering the CNS, 2 mice inoculated with SHI-1 cells and one
control mouse were sacrificed weekly after inoculation.
Reverse transcription-polymerase chain reaction (RT-PCR)
analysis and quantitative real-time polymerase chain
reaction (qRT-PCR)
Animals were anaesthetized with chloral hydrate and perfused
with PBS prior to sacrifice in order to avoid RNA contamination
from blood cells. Brains were immediately removed after perfusion
and total RNA was extracted using Trizol reagent according to the
manufacturer’s instruction, and cDNA were synthesized by using
MMLV reverse transcriptase (Gibco, USA). The oligonucleotide
primer sequences were designed as the follows: human MMP-2,
forward 59-GCT ATG GAC CTT GGG AGA A-39, reverse 59-
TGG AAG CGG AAT GGA AAC-39, product 260 bp; human
MMP-9, forward 59-TCC CTG GAG ACC TGA GAA CC-39,
reverse 59-CGG CAA GTC TTC CGA GTA GTT T-39, product
287 bp; human GAPDH, forward 59- AGA AGG CTG GGG
CTC ATT TG -39, reverse 59- AGG GGC CAT CCA CAG TCT
TC -39,product 258 bp. MLL/AF6 fusion genes were detected by
nested PCR performed as previously described [26]. The
amplified products were analyzed by 2% agarose gel electropho-
resis and photographed under UV light.
Levels of MMP-2 and MMP-9 mRNA were analyzed with the
TaqMan Gene Expression Assays (Applied Biosystems). Glyceral-
dehyde-3-phosphatedehydrogenase (GAPDH) housekeeping gene
was used as an endogenous control to correct potential variation in
RNA loading or efficiency of the amplification procedure. Primers
and probe specific for human MMP-2, MMP-9 and GAPDH used
as reported previously [24,27]. Real-time PCR was performed on
a MJ Research OpticonTM2. The PCR thermal cycle conditions
and calculation of the relative expression of mRNA species were
performed as described previously [24]. All samples were
measured in triplicate.
Histology and immunofluorescence
Bone marrow smears of mouse femurs were stained with
Wright’s-Giemsa for observing leukemic blast cells. Brains were
immediately removed after perfusion with 4% paraformaldehyde
(PFA) in PBS, pH 7.4, fixed for 3 h in 4%PFA in PBS at 4uC, and
incubated overnight in PBS with 20% sucrose at 4uC. Brains were
cut into 6 or 20 mm thick sections with a cryostat. Sections of 6 mm
thick were stained with hematoxylin and eosin (H&E). The
remaining slides were used for immunofluorescence.
Immunofluorescence analysis determined the changes of TJ
proteins in brain sections and BMVECs on Matrigel. Cell
monolayers cultured on inserts were washed in PBS and fixed with
4% PFA. After blocking with 1% or 5% BSA, cells or brain sections
were stained with primary monoclonal antibodies against ZO-1,
occludin and claudin-5, conjugated to FITC or Alexa 488
(Invitrogen, USA) overnight at 4uC. The primary antibodies were
used in a 1:50 dilution. For double labels, anti-fibrinogen (1:200,
Abcam, USA) goat monoclonal antibody or anti-CD31 (1:50,
Abcam, USA) rat monoclonal antibody were incubated with these
primary antibodies respectively. Incubation with the secondary
antibody Cy3-labelled anti-goat or anti-rat IgG (1:750) lasted for
1 h at 37uC. Nuclei were stained with DAPI (Molecular Probes,
Invitrogen) for 3 min. Staining was analyzed with a laser-scanning
confocal microscope (Nikon A1, Japan).
In situ gelatin zymography
The frozen, nonfixed sections from brain tissues were incubated in
a humidity chamber for 3 h at 37uC in a reaction buffer (0.05 M
Tris–HCl, 0.15 M NaCl, 5 mM CaCl, 0.2 mM NaN3) containing
20 mg/ml of fluorescein isothiocyanate (FITC)-labeled DQ-gelatin
(EnzCheckCollagenaseKit, Invitrogen, USA).As a negativecontrol,
50 mM of 1, 10-phenanthroline, a metalloproteinase inhibitor, was
added to the reaction buffer before applying the FITC-labeled DQ
gelatintofrozen sections. Afterincubation,fluorescence wasdetected
by laser scanning fluorescence confocal microscopy. Quenched
FITC molecules contained within the gelatinemit fluorescencewhen
the gelatin is enzymatically cleaved by MMP-2/-9.
Immunoblotting
Equal amounts of protein (80 mg) were loaded on 6 or 10%
polyacrylamide gels and SDS-PAGE was performed. After
separation by electrophorese, proteins were electroblotted on
polyvinyl difluoride membranes. The membranes were incubated
with primary monoclonal mouse antibodies against against ZO-1
(2 mg/ml; Inritrogen), Claudin-5 (3 mg/ml; Inritrogen), occludin
(2.5 mg/ml; Inritrogen) at 4uC overnight. After the blots were
incubated with secondary antibodies, bands were visualized by
using the ECL chemiluminescence detection system. The experi-
ment was repeated at least twice with independent protein samples.
Data analysis
Statistical analysis was carried out using ANOVA followed by
Tukey’s post hoc tests (GraphPad 4.0 Software, San Diego, CA).
Significance was assumed for p value less than 0.05.
Results
MMP-2 and -9 are expressed by different leukemic cell
lines and correlates with their invasive capacity
The qRT-PCR determination of mRNA expressions in SHI-1,
HL-60 and U937 cells revealed that the transcriptional level of
MMP-2 and -9 in SHI-1 cells were all markedly higher than that
in other leukemic cell lines (P,.001) (Fig. 1A). Furthermore, the
zymographic analysis of MMP-2 and -9 activities of the cell culture
supernatants were consistent with their mRNA levels. Moreover,
SHI-1 cells released a small portion of activated MMP-9 into
culture supernatants (Figure 1B). Cell migration assay was used to
Mechanism of Central Nervous System Leukemia
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of SHI-1 was significantly higher than that of HL-60 and U937
cells (P,.001) (Figure 1C).
Increased permeability of the BBB by leukemic cells and
down-regulation of endothelial TJ proteins via MMP-2
and -9 in vitro
We hypothesized that MMP-2 and -9 secreted by leukemic cells
induced the permeability of the BBB by disrupting the TJ proteins in
CNS leukemia.To test this hypothesis, we first seeded SHI-1, HL-60
and U937 cells into the upper compartment of the in vitro BBB
model,constitutedbyprimaryhumanBMVECstoformaco-culture
system. The results showed that before co-culture with SHI-1, HL-
60 and U937 cells, BMVECs became confluent with neighbouring
cells tightly packed against each other leaving no gaps. However,
after incubation for 24 h with leukemic cells, the tightness of the
BMVECs was disrupted, giving rise to a loss of cell-cell contact and
the formation of intercellular gaps (Fig. 2A1). The number of
leukemic cells across the barrier was calculated as the rate of invasive
in order to reflect the degree of BBB breakdown. The rates of
invasion of leukemic cells in this co-culture system were inconsistent
with their secreted MMP-2 and -9 activities and their ability to
invade. Where SHI-1 showed a higher invasion capacity than either
HL-60 or U937 cells (Fig. 2B). Interestingly, the degree of
morphological changes in BMVECs depicted in Figure 2A1
matched well with the rate of invasive of different leukemic cells.
SHI-1 cells caused the strongest disruptive effects on BMVECs and
the BBB.
To further determine whether MMP-2 and MMP-9 secreted by
leukemic cells played roles in increasing the permeability of
BMVECs and the BBB, SHI-1, HL-60 and U937 cells were
treated with the MMP inhibitor GM6001, which had been
previously shown to inhibit MMP-2 and -9 [27], before co-culture
with BMVECs in the in vitro BBB model. We found that the
intercellular gap of BMVECs, led by leukemic cells, became tight
(narrow) or even partially disappeared (Fig. 2A2). Consistently and
significantly, the number of leukemic cells across the BBB
decreased, reflecting a decided reversal in the impairment of the
BBB. Gelatin zymography of supernatants from GM6001-treated
leukemic cells demonstrated a distinct loss of MMP-2 and -9
enzyme activities, compared to the untreated supernatants,
thereby confirming the ability of GM6001 to block MMP-2 and
-9 activities (Fig. 2C). These results show that MMP-2 and -9
secreted by leukemic cells were closely related to the BBB
breakdown by disrupting BMVECs.
To define whether the breakdown of BBB induced by MMP-2
and -9 was led by changes in TJ in addition to the basement
membrane, BMVECs were immunostained for the TJ proteins
ZO-1, claudin-5 and occludin. Confocal imaging demonstrated
that in human BMVECs cultures, these proteins remained were
localized on the plasma membrane in areas of cell-cell contact
(Fig. 3A). After incubation with leukemic cells, the fluorescent
immunoreactivity for ZO-1, claudin-5 and occludin appeared
patchy or even faded away in those areas accompanied by the
same degree of BBB breakdown (Fig. 3B–D). On the contrary, the
expression of three proteins, all up-regulated in company with the
decreased BBB permeability when MMP-2 and -9 were secreted
by leukemic cells was inhibited by GM6001 (Fig. 3B–D).
Collectively, these results suggested that leukemic cells disrupted
the BBB by down-regulating the TJ proteins ZO-1, claudin-5 and
occludin in BMVECs. MMP-2 and -9 secreted by leukemic cells
play important roles in this process.
Figure 1. Expression of MMP-2 and -9, gelatinase secretion and invasion rate in different leukemic cells. (A) qRT-PCR analysis of MMP-2
(A1) and MMP-9 (A2) gene transcription in SHI-1, HL-60 and U937 leukemic cells. (B) Gelatinase secretion from culture supernatants of three leukemic
cells. (C) Cell invasion rates of SHI-1, HL-60 and U937 leukemic cells. Cell invasion rates were determined by the ratios relative to SHI-1 cells. Data
represent the mean 6 SD of triplicate measurement representative for three independent experiments relative to SHI-1 cells (set as 100%). Compare
with SHI-1 cells *P,.001.
doi:10.1371/journal.pone.0020599.g001
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or -9 genes and decreased disruption of ZO-1, claudin-5
and occludin with alleviative permeability of in vitro BBB
To elucidate the specific contribution of MMP-2 and -9 in the
role of the BBB opening, we silenced the genes expression of
MMP-2 and -9 in SHI-1 cells by means of RNAi. The down-
regulation of the mRNA expression was still effective with levels
between 60% and 65% when determined 24 h after treatment
with the respective siRNAs (Figure 4A). These results were
confirmed by zymographic analysis of cultured supernatants and
demonstrated successful blockage of MMP-2 and -9 productions
(Figure 4B). Down-regulation of MMP-2 and -9 also impaired the
invasive capacity of SHI-1 cells (data not shown). Furthermore, to
examine the BBB disruption related to MMP-2 and -9 secreted by
SHI-1 cells, RNAi-treated SHI-1 cells were cultured with
BMVECs in the in vitro model of BBB. As shown in Fig. 4C, the
rate of invasion of SHI-1 cells reduced when MMP-2 or -9 genes
were knocked-down, which showed the relative weaker disruption
of the BBB (P,.001). Consistently, immunofluorescence for ZO-1,
Figure 2. Increased in vitro BBB permeability due to MMP-2 and -9 secreted by SHI-1, HL-60 and U937 cells. (A) Morphological changes
of BMVECs affected by SHI-1, HL-60 and U937 cells treated with or without GM6001. (B) Rates of leukemic cell invasion of co-culture with BMEVCs
compared with those of monoculture (without BMEVCs) (P..05) and those treated with GM6001 (*P,.001). Results are shown as the mean 6 SD of
three independent experiments. (C) Zymography gelatinase secretion in SHI-1, HL-60 and U937 cells treated with or without GM6001. Original
magnification: (A)6600.
doi:10.1371/journal.pone.0020599.g002
Figure 3. Confocal imaging showed protein localization of ZO-1, claudin-5 and occludin in human BMEVCs. (A) Confocal imaging of
ZO-1, claudin-5 and occludin of human BMEVCs; (B, C, D) BMEVCs co-cultured with SHI-1, HL-60 and U937 cells with or without treatment by GM6001.
(E) BMEVCs of co-cultured with SHI-1 cells after knock-down of the MMP-2/MMP-9 gene. Data in all panels are representative of at least 3 separate
experiments on 3 distinct cultures. (Scale bars: 10 mm).
doi:10.1371/journal.pone.0020599.g003
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gene partially relieved the degradation of TJ proteins (Fig. 3E).
The morphological changes of BMEVCs also demonstrated this
phenomenon (data not shown) Thus, these findings demonstrate
that down-regulation of gene expression of MMP-2 or -9 in SHI-1
cells could partially reverse the disruption of ZO-1, claudin-5 and
occludin and so decrease the permeability of the BBB. These
results further confirm the roles of MMP-2 and -9 in disrupting the
BBB by degrading TJ proteins.
Fatal CNS leukemia in SCI-nu/nu mice caused by the
human acute monocytic leukemia cell line SHI-1
In order to investigate whether the BBB breakdown in CNS
leukemia was associated with changes in endothelial TJ proteins in
vivo, we next established a mouse model of CNS leukemia with the
highlyinvasivehumanacutemonocyticleukemia cellline SHI-1.Of
the 20 surviving mice (other 10 mice were sacrificed weekly)
challenged with SHI-1 cells, 11 mice developed symptomatic CNS
leukemia. The prominent clinical sign of CNS leukemia was muscle
weakness in the legs with a slight lowering of the lower back.
Subsequently, mice developed a rapidly progressive paralysis of the
cranial nerve with or without sight loss and they were no longer able
to obtain food or water at (32.5560.65) d (mean 6SD) after being
challenged by SHI-1 (Fig. 5A). They were killed when mice were
moribund. Intracerebral mass or chloroma with or without
intracranial hemorrhage was found in the removed brains
(Fig. 5B). Histopathology examination showed that the CNS was
extensively involved in these mice, with leukemic cell infiltrating the
brain parenchyma (Fig. 5C1–C3) and subarachnoid spaces or
accumulated on the surface of the cerebrum (data not shown). Bone
marrow smear demonstrated a lot of leukemia blasts, infiltrating the
bone marrow (Fig. 5C4). Histopathology also demonstrated the
infiltration by SHI-1 cells in livers, lungs, kidneys, testes, hearts and
other organs (data not shown).
SHI-1 cells have t (6; 11) (q27; q23) and the rearrangement of the
MLL gene, expressing the MLL/AF6 fused gene product [22].
MLL/AF6 was initially amplified in the brain at day 21 after
challenged SHI-1 in some mice. The transcription of MLL/AF6
fusion gene also could be detected in the brains and bone marrows of
killed mice with paralysis (Fig. 5D1). In control mice and mice
without CNS leukemia, we did not examine for MLL/AF6 fusion
gene in brains. All of our data demonstrate that the animal model of
Figure 4. Effects of MMP-2/MMP-9 knock-down on activity of gelatinase and rates of cell invasion by SHI-1 in the in vitro BBB model.
(A) Transcription of specific mRNAs quantified by qRT-PCR 48 h after siRNA transfection. SHI-1 cells transfected with siRNAs targeting the expression
of MMP-2 (KD-MMP-2) or (B) MMP-9 (KD- MMP-9). Control SHI-1 cells transfected with non-target-directed siRNA (set as 100%). (C) Gelatinase
secretion from SHI-1 cells transfected with siRNAs. (D) Rates of cell invasion of SHI-1 cells 48 h after transfection with siRNA in in vitro model of BBB.
Data represent the mean 6 SD of triplicate measurement representative for three independent experiments relative to SHI-1 cells (set as 100%).
*P,.001.
doi:10.1371/journal.pone.0020599.g004
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establishedwiththehumanacutemonocyticleukemiccelllineSHI-1.
GM6001 protected mice against CNS leukemia
Consistent with MLL/AF6, the human MMP-2 and -9
transcriptions were initially detected at day 21 after being
challenged by SHI-1 and amplified in all killed mice with CNS
leukemia (Fig. 6A). In order to examine the roles of MMP-2 and -
9, GM6001 was used to inject intraperitoneally into mice. We
found that no mice developed CNS leukemia until they were killed
when moribund at (41.5061.62) d (mean 6SD) after being
challenged by SHI-1. The number of organs infiltrated by SHI-1
cells and the degree of infiltration also decreased (Fig. 5D). MMP-
2 and -9 transcripts were not detected in the brains of mice treated
with GM6001. (Fig. 6A). Furthermore, we used in situ zymography
to identify the regions with gelatinolytic activity. Bright fluorescent
(green) spots were apparent in the areas of infiltration with
leukemic cells and in the periphery of mouse brains with CNS
leukemia (Fig. 6C). While after treatment with GM6001,
gelatinolytic activities had not changed in all mice compared with
Figure 5. The SCI-nu/nu mice model of CNS leukemia. (A) Clinical signs of CNS leukemia in mice. (A1, A2, arrow) The mouse developed
paralysis in its left forelimb and cranial nerve with light loss. (A3, arrow) The mice developed paralysis in both fore limbs and hind limbs. (B, arrow)
Neoplasms of different parts with or without intracranial hemorrhage in removed brains. (C) Infiltrations of SHI-1 examined with histopathology assay.
(C1, C2, C3) Brain parenchyma pathobiology stained with H&E. (C4) Examination of bone marrow smears stained with Wright’s-Giemsa. (D) Organs
with infiltrations of SHI-1 examined with RT-PCR analysis of human MLL/AF6 fusion gene transcription in mice with or without GM6001 treatment.
(D1) RT-PCR analysis of MLL/AF6 fusion gene of brains and bone marrow from SCI nu/nu-mice. Lanes 1–5: Human MLL/AF6 fusion genegene
amplified in SHI-1 cell and in brain, bone marrow, stomach and liver of mice with CNS leukemia. lane 6–9: Human MLL/AF6 fusion gene amplified in
stomach, liver, brain and bone marrow of mice with GM6001 treatment. lane 10: negative control. (D2) The number of organs with infiltrations of SHI-
1 examined with RT-PCR analysis of human MLL/AF6 fusion gene transcription in mice with or without GM6001 treatment. Original magnification:
(C1), 640; (C2), 6200; (C3), 61000; (C4), 61000.
doi:10.1371/journal.pone.0020599.g005
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brain sections (Fig. 6B, D). These data demonstrate that MMP-2
and -9 secreted by SHI-1 cells play important roles in leukemic cell
infiltration to CNS and other extramedullary infiltration.
BBB breakdown with the disruption of endothelial TJ
proteins in CNS leukemia and GM6001 reversed these
changes
To investigate whether BBB breakdown in CNS leukemia is
associated with changes in endothelial TJ proteins, brain tissue
sections were immunostained for ZO-1, claudin-5 and occludin,
plus fibrinogen as a marker of the BBB disruption. Fibrinogen is a
serum protein which is absent in the CNS under normal
physiological conditions. Confocal imaging of the brain cortex
from normal control mice showed that ZO-1, claudin-5 and
occludin localized to linear profiles, were confirmed as vessels
using the CD31 antigen (Fig. 7A, B1). In brains of mice with
leukemic cell infiltration, confocal imaging showed widespread
BBB breakdown as assessed by parenchymal immunoreactivity for
fibrinogen (Fig. 7B2). Importantly, ZO-1, claudin-5 and occludin
immunoreactivity also appeared reduced in these areas (Fig. 7B2).
Moreover, immunoblotting for ZO-1, claudin-5 and occludin
showed that the protein levels were down-regulated in brains with
CNS infiltration than in normal mice brains (Fig. 7C). However,
these three TJ proteins did not change in the brain of mice with
GM6001 treatment compared with normal control mice (data not
shown). In accordance with the results of immunoreactivity, the
protein levels did not change after MMP-2 and -9 were inhibited
by GM6001 (Fig. 7C). Collectively, these results demonstrate that
the loss of endothelial TJ proteins ZO-1, claudin-5 and occludin
leaded by MMP-2 and -9 is a central event in the opening of the
BBB in CNS leukemia.
Discussion
In this study, we have investigated the mechanism underlying
the BBB breakdown which makes leukemic cell enter the CNS
during the process of leukemic cell extramedullary infiltration.
We conclude that MMP-2 and -9 secreted by leukemic cells have
been implicated in the response. The targets of the MMP-2 and -
9 are the endothelial TJ proteins in addition to the well-known
ECM. MMP-2 and -9 distinguishably disrupted the TJ proteins
ZO-1, claudin-5 and occludin as the BBB breakdown. We also
have shown that these alterations can be inhibited by the
broadband MMP inhibitor GM6001 and the knock-down of
MMP-2/MMP-9 genes. Furthermore, GM6001 could effectively
protect the mice against CNS leukemia. These findings may
Figure 6. Activities of MMP-2 and -9 secreted by SHI-1 with or without GM6001 treatment in CNS leukemia mice. (A) RT-PCR analysis of
human MMP-2 and -9 gene transcription in normal brain tissues, brain tissues infiltrated with SHI-1 cells with or without GM6001 treatment. (B, C and
D) In situ zymographic analysis of MMP-2 and -9 activities mouse tissues. (B) Normal brain tissues; (C) Brain tissues infiltrated with SHI-1 cells; (D) Brain
tissues after treatment with GM6001. Results shown are from individual animals and are representative of findings from 3 experiments with 6 animals
per condition per experiment. (Scale bars: 10 mm).
doi:10.1371/journal.pone.0020599.g006
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leukemia.
The invasion process of cancer cells involves the secretion of
substances to degrade the components of the extracellular matrix,
as well as the proteins involved in the control of motility and
migration [28]. It is well-known that MMP-2 and -9 play critical
roles in solid tumor invasion. For leukemia, the blasts circulating in
the bloodstream, must have different invasive characteristics. Our
previous study and other evidence implicated abnormal expression
of MMP-2 and -9 in AML and their correlation with the
extramedullary infiltration [15,16,27]. Reikvam H et al. reported
that MMP-9 release was higher in AML cells with monocytic
differentiation corresponding to the FAB-subtype M4/M5 AML
[29]. Paupert et al. also found that a surface-bound MMP-9 form
may contribute to the invasive capacities of monocytic leukemia
(M4 and M5) cells in vitro and their extramedullary infiltration
including CNS leukemia in vivo [30]. The continuous complexes of
TJs combined with reduced vesicular transport make the BBB are
Figure 7. Increased BBB disruption, with a decrease in endothelial ZO-1, claudin-5 and occludin, avoided by GM6001. (A) Confocal
imaging of cerebral cortex from normal mice immunostained for ZO-1 localize at vessels, confirming the use of CD31. (B1, B2) Confocal imaging of TJ
proteins ZO-1, claudin-5, occludin and fibrinogen in brain parenchyma in control and CNS leukemia mice. (C) Immunoblots of protein extracts from
brains of control mice, 4 CNS leukemia mice with brain parenchyma and CNS leukemia mice treated with GM6001. In all figures, brain tissues of
normal mice used as control. (D) Model of MMP-2 and -9 secreted by leukemic cells disrupting several key TJ proteins of BMVECs in BBB breakdown.
Results shown are from individual animals and are representative of findings from 3 experiments with 4 animals per condition per experiment. (Scale
bars: 10 mm).
doi:10.1371/journal.pone.0020599.g007
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selects for leukemic cells that express the necessary extravasation
functions. Although reports have shown that MMP-2 and -9 are
closely associated with the BBB disruption in some CNS related
diseases [20,31], little is known about the pathological role of
MMP-2 and -9 secreted by leukemic cells in BBB breakdown in
CNS leukemia.
In order to investigate the relationship between leukemic cell-
derived MMP-2 and -9 and the BBB in CNS leukemia, we first
studied the effect of MMP-2 and -9 secreted by different leukemic
cells on cultured BMVECs in the in vitro model of the BBB.
Before transmembrane of leukemic cells, we seeded BMVECs
onto the upper surface of matrigel-coated polycarbonate
membranes in transwell culture chambers to simulate the barrier
of the BBB. Cultured BMVECs retain many of the features of the
BBB and have been used as in vitro models to study mechanisms
that regulate the permeability of the BBB [32,33]. It is well-
known that BBB is maintained primarily by TJs between adjacent
microvascular endothelial cell images as a network of strands
formed by intramembranous particles and occlude intercells more
effectively [10,11,34]. The transmembrane proteins occludin and
claudin-5 form the primary seal of the TJs. They bind to the ZO-
1 and other proteins that couple the TJs to the actin cytoskeleton
of endothelial cells [10]. Studies have demonstrated a correlation
between the reduction of TJ and tumor differentiation and placed
TJ in the frontline as the structure that cancer cells must
overcome in order to metastasize [28,35,36]. We also found that
each of the different leukemic cell lines HL-60, SHI-1 and U937
all could disrupt the TJ proteins ZO-1, claudin-5 and occludin,
accompanying the formation of intercellular gaps in co-cultured
BMVECs and the breakdown of BBB, but the levels of disruption
differed greatly. SHI-1 cells displayed a stronger capacity of
disrupting TJ proteins than the other two leukemic cell lines,
consistent with its higher rate of invasion which is closely related
to the constitutive strong expression of MMP-2 and -9. GM6001
is a broad-spectrum MMP inhibitor to prevent the activities of
MMP-2, -3, -8 and -9 and is routinely used to understand the
pathogenic roles of MMP-2 and -9 [23,37]. We have shown that
GM6001 blockaded the activities of MMP-2 and -9 and
significantly decreased the disruption of the leukemic cells to
the TJ proteins. Moreover, the knock-down of MMP-2 or MMP-
9 genes by iRNA in SHI-1 cells also reduce the disruption of
those proteins and the permeability of BBB. These findings
suggest that MMP-2 and -9 secreted by leukemic cells can
degrade components of TJ in addition to basement membranes,
which help the leukemic cells to infiltrate the brain.
Our previous study has created an efficient and reproducible
experimental model of AML CNS leukemia and multiorgan
infiltration by using highly invasive SHI-1 cells in nu/nu mice
[26]. However, a mouse model of CNS leukemia can not be
successfully established with HL-60 and U937 cells. In this study
we increased the number of inoculated SHI-1 cells. More than
half of the mice developed CNS leukemia and 4 of them had
SHI-1 cell infiltration in the brain parenchyma. In the section of
infiltrarion with SHI-1 cells, we found a widespread BBB
breakdown with a loss of the endothelial TJ proteins ZO-1,
claudin-5 and occludin. The accompanying up-regulation of
human MMP-2 and -9 showed that MMP-2 and -9 secreted by
SHI-1 cells played an important role in this event. Surprisingly,
GM6001 protected mice against CNS leukemia and as well, other
organs were protected and no mice developed CNS leukemia.
These results further defined that MMP-2 and -9 secreted by
leukemic cells increased the permeability of the BBB by
disrupting the TJ proteins ZO-1, claudin-5 and occludin in
CNS leukemia.
We also found that both MMP inhibitor GM6001 and the
RNAi technology to inhibit the expression of MMP-2 and -9 in
leukemic cells could not entirely reverse the disruption of the TJ
proteins and the permeability of the BBB in vitro. In addition to
MMP-2 and -9, other MMP family members such as MMP-1,
MMP-3, MMP-11 and MMP-14 have all been shown to be
secreted by tumor cells in tumor microenvironments, serving to
mediate the breakthrough of tissue barriers comprising cell–cell
adherent junctions, basement membranes, and interstitial tissue
stroma [38–40]. Furthermore, the invasive behavior of tumor cells
depends not only upon the secretion of a variety of degradative
enzymes but also on the alterations in the expression of adhesion
molecules (selectin–selectin ligand axis), the responses to cytokines
and chemokines (CXCR4, CCR7, et al.) and the gene products
regulating motility. Multiple mechanisms appear to contribute to
the disease.
The integral transmembrane proteins such as claudin-5 and
occludin are the essential adhesion proteins responsible for
correct assembly of the TJ structure of the BBB and controlling
TJ functions via homotypic and heterotypic interactions [10,28].
There is an ongoing interest in the question of how the TJ
proteins are modified by MMP-2 and -9 as it occurs in CNS
leukemia. ZO-1, claudin-5 and occludin cleavage by MMPs is a
possible mechanism underlying BBB impairment and has been
detected in vivo models of focal cerebral ischemia [18,41,42]. Both
occludin and claudin-5 consist of four transmembrane domains,
intracellular N- and C-termini, and two extracellular domains
that might interact with cell membranes of vicinal cells thus
sealing the intercellular clefts [43,44]. The first extracellular loop
displayed type IV collagenase sensitive motives, implying that
claudin-5 and occludin cleavage might be caused by MMP-2 or -
9 [45,46]. In addition to the most important functions as a barrier
to cell migration, TJs have been linked to various signaling
mechanisms [44], hence possible mechanisms will be further
investigated.
In conclusion, our results established a correlation between
MMP-2 and -9 secreted by leukemic cells and the disruption of the
TJ proteins ZO-1, claudin-5 and occludin, which increases
paracellular permeability of leukemic cell across the BBB in
CNS leukemia. This information provides an important mecha-
nism of leukemic cell infiltration of the CNS, which may provide
additional insight into its potential target for therapeutic
intervention. Future studies will have to clarify the precise
mechanism or signal transduction pathway for the permeability-
increasing effect of leukemic cell-derived MMP-2 and -9.
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